199 related articles for article (PubMed ID: 19074889)
1. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.
Shi Y; Frost PJ; Hoang BQ; Benavides A; Sharma S; Gera JF; Lichtenstein AK
Cancer Res; 2008 Dec; 68(24):10215-22. PubMed ID: 19074889
[TBL] [Abstract][Full Text] [Related]
2. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.
Shi Y; Frost P; Hoang B; Benavides A; Gera J; Lichtenstein A
J Biol Chem; 2011 Jan; 286(1):67-78. PubMed ID: 20974848
[TBL] [Abstract][Full Text] [Related]
3. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.
Shi Y; Sun F; Cheng Y; Holmes B; Dhakal B; Gera JF; Janz S; Lichtenstein A
Mol Cancer Ther; 2022 Apr; 21(4):502-510. PubMed ID: 35086951
[TBL] [Abstract][Full Text] [Related]
4. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.
Martin J; Masri J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Anderson L; Bashir T; Bernath A; Lichtenstein A; Gera J
J Biol Chem; 2011 May; 286(18):16402-13. PubMed ID: 21454539
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling.
Jo OD; Martin J; Bernath A; Masri J; Lichtenstein A; Gera J
J Biol Chem; 2008 Aug; 283(34):23274-87. PubMed ID: 18562319
[TBL] [Abstract][Full Text] [Related]
6. Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation.
Lewis SM; Veyrier A; Hosszu Ungureanu N; Bonnal S; Vagner S; Holcik M
Mol Biol Cell; 2007 Apr; 18(4):1302-11. PubMed ID: 17287399
[TBL] [Abstract][Full Text] [Related]
7. PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1.
Gao G; Dhar S; Bedford MT
Nucleic Acids Res; 2017 May; 45(8):4359-4369. PubMed ID: 28115626
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.
Shi Y; Yang Y; Hoang B; Bardeleben C; Holmes B; Gera J; Lichtenstein A
Oncogene; 2016 Feb; 35(8):1015-24. PubMed ID: 25961916
[TBL] [Abstract][Full Text] [Related]
9. hnRNP A1 mediates the activation of the IRES-dependent SREBP-1a mRNA translation in response to endoplasmic reticulum stress.
Damiano F; Rochira A; Tocci R; Alemanno S; Gnoni A; Siculella L
Biochem J; 2013 Jan; 449(2):543-53. PubMed ID: 23106379
[TBL] [Abstract][Full Text] [Related]
10. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
Shi Y; Frost P; Hoang B; Yang Y; Fukunaga R; Gera J; Lichtenstein A
Oncogene; 2013 Jan; 32(2):190-7. PubMed ID: 22370634
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
Holmes B; Lee J; Landon KA; Benavides-Serrato A; Bashir T; Jung ME; Lichtenstein A; Gera J
J Biol Chem; 2016 Jul; 291(27):14146-14159. PubMed ID: 27226604
[TBL] [Abstract][Full Text] [Related]
12. sST2 translation is regulated by FGF2 via an hnRNP A1-mediated IRES-dependent mechanism.
Kunze MM; Benz F; Brauß TF; Lampe S; Weigand JE; Braun J; Richter FM; Wittig I; Brüne B; Schmid T
Biochim Biophys Acta; 2016 Jul; 1859(7):848-59. PubMed ID: 27168114
[TBL] [Abstract][Full Text] [Related]
13. Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1.
Cobbold LC; Wilson LA; Sawicka K; King HA; Kondrashov AV; Spriggs KA; Bushell M; Willis AE
Oncogene; 2010 May; 29(19):2884-91. PubMed ID: 20190818
[TBL] [Abstract][Full Text] [Related]
14. m
Benavides-Serrato A; Saunders JT; Kumar S; Holmes B; Benavides KE; Bashir MT; Nishimura RN; Gera J
Cancer Lett; 2023 May; 562():216178. PubMed ID: 37061119
[TBL] [Abstract][Full Text] [Related]
15. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.
Frost P; Shi Y; Hoang B; Gera J; Lichtenstein A
Mol Cancer Ther; 2009 Jan; 8(1):83-93. PubMed ID: 19139116
[TBL] [Abstract][Full Text] [Related]
16. Annexin A2 binds the internal ribosomal entry site of c-
Strand E; Hollås H; Sakya SA; Romanyuk S; Saraste MEV; Grindheim AK; Patil SS; Vedeler A
RNA Biol; 2021 Oct; 18(sup1):337-354. PubMed ID: 34346292
[TBL] [Abstract][Full Text] [Related]
17. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo.
Evans JR; Mitchell SA; Spriggs KA; Ostrowski J; Bomsztyk K; Ostarek D; Willis AE
Oncogene; 2003 Sep; 22(39):8012-20. PubMed ID: 12970749
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous nuclear ribonucleoprotein A1 is a novel internal ribosome entry site trans-acting factor that modulates alternative initiation of translation of the fibroblast growth factor 2 mRNA.
Bonnal S; Pileur F; Orsini C; Parker F; Pujol F; Prats AC; Vagner S
J Biol Chem; 2005 Feb; 280(6):4144-53. PubMed ID: 15525641
[TBL] [Abstract][Full Text] [Related]
19. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
20. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation.
Chappell SA; LeQuesne JP; Paulin FE; deSchoolmeester ML; Stoneley M; Soutar RL; Ralston SH; Helfrich MH; Willis AE
Oncogene; 2000 Sep; 19(38):4437-40. PubMed ID: 10980620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
